Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302.
Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302.
复制标题
二甲双胍和他汀类药物对去势抵抗性转移性前列腺癌患者预后的影响：coua - aa -301和coua - aa -302的二次分析
DOI：
10.1016/j.ejca.2022.03.042
复制
发表时间：
2022-07
影响因子：
8.4
通讯作者：
Joshua, Anthony M.
中科院分区：
文献类型：
--
作者：
Wilson, Brooke E.;Armstrong, Andrew J.;de Bono, Johann;Sternberg, Cora N.;Ryan, Charles J.;Scher, Howard, I;Smith, Matthew R.;Rathkopf, Dana;Logothetis, Christopher J.;Chi, Kim N.;Jones, Robert J.;Saad, Fred;De Porre, Peter;Tran, NamPhuong;Hu, Peter;Gillessen, Silke;Carles, Joan;Fizazi, Karim;Joshua, Anthony M.
在转移性去势抵抗性前列腺癌试验中，二甲双胍和他汀类药物与总生存期（OS）和前列腺特异性抗原应答率（PSA-RR）的相关性尚不清楚。确定二甲双胍或他汀类药物±醋酸阿比特龙+泼尼松/泼尼松龙（AAP）是否影响OS和PSA-RR。COU-AA-301和COU-AA-302患者按二甲双胍和他汀类药物使用进行分层。采用考克斯比例风险模型估计按合并用药分层的风险比（HR），采用随机效应模型汇总HR，采用卡方χ2检验比较PSA RR。在COU-AA-301-AAP中，二甲双胍与PSA-RR改善相关（41.1% vs 28.6%），但与OS延长无关。在COU-AA-301-安慰剂-P中，二甲双胍与OS或PSA-RR延长无关。在COU-AA-302-AAP中，二甲双胍与OS延长（adjHR 0.69，95% CI 0.48-0.98）和PSA-RR改善（72.7% vs 60.0%）相关。在COU-AA-302-P中，二甲双胍与OS延长相关（adjHR 0.66，95% CI 0.47-0.93）。在汇总分析中，二甲双胍治疗组的OS延长（合并HR 0.77，95% CI 0.62-0.95）。在COU-AA-301-AAP中，他汀类药物与OS改善相关（adjHR 0.76，95% CI 0.62-0.93），而COU-AA-301-P组无差异。COU-AA-302组与他汀类药物和OS均无相关性。当汇总HR时，他汀类药物治疗组的OS延长（汇总HR 0.78，95% CI 0.68-0.88）。在事后亚组分析的局限性内，二甲双胍和他汀类药物与OS延长和PSA-RR增加相关，尤其是与AAP联合使用。
The associations of metformin and statins with overall survival (OS) and prostate specific antigen response rate (PSA-RR) in trials in metastatic castration-resistant prostate cancer remain unclear. To determine whether metformin or statins ± abiraterone acetate plus prednisone/prednisolone (AAP) influence OS and PSA-RR. COU-AA-301 and COU-AA-302 patients were stratified by metformin and statin use. Cox proportional hazards models were used to estimate hazards ratio (HR) stratified by concomitant medications, and a random effects model was used to pool HR. We compared PSA-RR using Chi χ2 test. In COU-AA-301-AAP, metformin was associated with improved PSA-RR (41.1% versus 28.6%) but not prolonged OS. In COU-AA-301-placebo-P, there was no association between metformin and prolonged OS or PSA-RR. In COU-AA-302-AAP, metformin was associated with prolonged OS (adjHR 0.69, 95% CI 0.48–0.98) and improved PSA-RR (72.7% versus 60.0%). In COU-AA-302-P, metformin was associated with prolonged OS (adjHR 0.66, 95% CI 0.47–0.93). In pooled analysis, OS was prolonged among those treated with metformin (pooled HR 0.77, 95% CI 0.62–0.95).In COU-AA-301-AAP, statins were associated with an improved OS (adjHR 0.76, 95% CI 0.62–0.93), while there was no difference in COU-AA-301-P. There was no association with statins and OS in either COU-AA-302 groups. When pooling HR, OS was prolonged among those treated with statins (pooled HR 0.78, 95% CI 0.68–0.88). Within the limitations of post-hoc sub-analyses, metformin and statins are associated with a prolonged OS and increased PSA-RR, particularly in combination with AAP.
登录
查看更多内容
DOI：
10.1056/nejmoa1315815
发表时间：
2014-09-11
期刊：
The New England journal of medicine
影响因子：
--
作者：
Antonarakis ES;Lu C;Wang H;Luber B;Nakazawa M;Roeser JC;Chen Y;Mohammad TA;Chen Y;Fedor HL;Lotan TL;Zheng Q;De Marzo AM;Isaacs JT;Isaacs WB;Nadal R;Paller CJ;Denmeade SR;Carducci MA;Eisenberger MA;Luo J
通讯作者：
Luo J
影响因子：
2.3
作者：
Wright, Jonathan L.;Stanford, Janet L.
通讯作者：
Stanford, Janet L.
二甲双胍通过靶向 TGF-β 1/STAT3 轴调节的 EMT 逆转前列腺癌对恩杂鲁胺的耐药性
影响因子：
9
作者：
Liu Q;Tong D;Liu G;Xu J;Do K;Geary K;Zhang D;Zhang J;Zhang Y;Li Y;Bi G;Lan W;Jiang J
通讯作者：
Jiang J
DOI：
10.1002/pros.23390
发表时间：
2017-05
期刊：
The Prostate
影响因子：
--
作者：
Harshman LC;Werner L;Tripathi A;Wang X;Maughan BL;Antonarakis ES;Nakabayashi M;McKay R;Pomerantz M;Mucci LA;Taplin ME;Sweeney CJ;Lee GM;Kantoff PW
通讯作者：
Kantoff PW
DOI：
10.1056/nejmoa1209096
发表时间：
2013-01-10
期刊：
The New England journal of medicine
影响因子：
--
作者：
Ryan CJ;Smith MR;de Bono JS;Molina A;Logothetis CJ;de Souza P;Fizazi K;Mainwaring P;Piulats JM;Ng S;Carles J;Mulders PF;Basch E;Small EJ;Saad F;Schrijvers D;Van Poppel H;Mukherjee SD;Suttmann H;Gerritsen WR;Flaig TW;George DJ;Yu EY;Efstathiou E;Pantuck A;Winquist E;Higano CS;Taplin ME;Park Y;Kheoh T;Griffin T;Scher HI;Rathkopf DE;COU-AA-302 Investigators
通讯作者：
COU-AA-302 Investigators